Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

INSM1 Expression in Primary and Metastatic Neuroendocrine Neoplasms of the Gastrointestinal and Pancreatobiliary Tracts.

González I, Lu HC, Sninsky J, Yang C, Bishnupuri K, Dieckgraefe B, Cao D, Chatterjee D.

Histopathology. 2019 May 11. doi: 10.1111/his.13899. [Epub ahead of print]

PMID:
31077609
2.

Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens.

Doxtader EE, Mukhopadhyay S.

Cancer Cytopathol. 2018 Apr;126(4):243-252. doi: 10.1002/cncy.21972. Epub 2018 Jan 23.

3.
4.

Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.

Tanigawa M, Nakayama M, Taira T, Hattori S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, Okabe Y, Hisaka T, Okuda K, Fujino K, Ito T, Kawahara A, Naito Y, Yamaguchi R, Akiba J, Akagi Y, Yano H.

Med Mol Morphol. 2018 Mar;51(1):32-40. doi: 10.1007/s00795-017-0167-6. Epub 2017 Aug 28.

PMID:
28849340
5.

INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.

Rooper LM, Sharma R, Li QK, Illei PB, Westra WH.

Am J Surg Pathol. 2017 Nov;41(11):1561-1569. doi: 10.1097/PAS.0000000000000916.

PMID:
28719469
6.

Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.

Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A.

World J Surg. 2014 Jun;38(6):1353-61. doi: 10.1007/s00268-014-2451-0.

PMID:
24493070
7.

Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.

Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H, Longuespée R, Kriegsmann J, Warth A, Kriegsmann M.

Appl Immunohistochem Mol Morphol. 2018 Oct 24. doi: 10.1097/PAI.0000000000000715. [Epub ahead of print]

PMID:
30358615
8.

A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.

Leblebici C, Yeni B, Savli TC, Aydın Ö, Güneş P, Cinel L, Şimşek BÇ, Yıldız P, Tuncel D, Kayahan S.

Ann Diagn Pathol. 2019 Jun;40:53-58. doi: 10.1016/j.anndiagpath.2019.04.002. Epub 2019 Apr 11.

PMID:
31031215
9.

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B, Xue W.

Hum Pathol. 2018 Sep;79:151-159. doi: 10.1016/j.humpath.2018.05.014. Epub 2018 Jun 6.

PMID:
29885405
10.

INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma.

Lilo MT, Chen Y, LeBlanc RE.

Am J Surg Pathol. 2018 Nov;42(11):1541-1548. doi: 10.1097/PAS.0000000000001136.

PMID:
30080705
11.

Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.

Roy M, Buehler DG, Zhang R, Schwalbe ML, Baus RM, Salamat MS, Lloyd RV, Rosenbaum JN.

Endocr Pathol. 2019 Mar;30(1):35-42. doi: 10.1007/s12022-018-9559-y.

PMID:
30523500
12.

INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.

Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV.

Am J Clin Pathol. 2015 Oct;144(4):579-91. doi: 10.1309/AJCPGZWXXBSNL4VD.

PMID:
26386079
13.

A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.

Kuji S, Watanabe R, Sato Y, Iwata T, Hirashima Y, Takekuma M, Ito I, Abe M, Nagashio R, Omae K, Aoki D, Kameya T.

Gynecol Oncol. 2017 Feb;144(2):384-390. doi: 10.1016/j.ygyno.2016.11.020. Epub 2016 Nov 28.

PMID:
27908529
14.

Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.

Rodriguez EF, Fite JJ, Chowsilpa S, Maleki Z.

Hum Pathol. 2019 Mar;85:128-135. doi: 10.1016/j.humpath.2018.10.035. Epub 2018 Nov 28.

PMID:
30502379
15.

Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.

Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J.

Medicine (Baltimore). 2014 Dec;93(27):e247. doi: 10.1097/MD.0000000000000247.

16.

Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.

Er LM, Li Y, Wu ML, Zhao Q, Tan BB, Wang XL, Wang SJ.

Oncol Lett. 2017 Apr;13(4):2391-2396. doi: 10.3892/ol.2017.5735. Epub 2017 Feb 14.

17.

INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors.

Rooper LM, Bishop JA, Westra WH.

Am J Surg Pathol. 2018 May;42(5):665-671. doi: 10.1097/PAS.0000000000001037.

PMID:
29438167
18.

[The diagnostic value of plasma chromogranin A in neuroendocrine tumors].

Yang XO, Li JN, Qian JM, Yang H, Chen Q, Lu L.

Zhonghua Nei Ke Za Zhi. 2011 Feb;50(2):124-7. Chinese.

PMID:
21418832
19.

The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study.

Stemann Lau T, Dam G, Jepsen P, Grønbæk H, Krogh K, Gregersen T.

Neuroendocrinology. 2018;107(3):280-283. doi: 10.1159/000492786. Epub 2018 Aug 9.

PMID:
30092588
20.

Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.

Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A.

PLoS One. 2017 Dec 12;12(12):e0188876. doi: 10.1371/journal.pone.0188876. eCollection 2017.

Supplemental Content

Support Center